Here are what the editors at HealthDay consider to be the most important developments in Pulmonology for October 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Link Between Statins, Non-CVD Outcomes Lacks Evidence
WEDNESDAY, Oct. 31, 2018 (HealthDay News) — There is a lack of convincing evidence for an association between statin use and non-cardiovascular disease (CVD) outcomes, according to a review published in the Oct. 16 issue of the Annals of Internal Medicine.
Abstract/Full Text (subscription or payment may be required)
AMA Announces Initiative to Reinvent Physician Training
TUESDAY, Oct. 30, 2018 (HealthDay News) — The American Medical Association (AMA) today announced a new $15 million competitive grant initiative, the “Reimagining Residency” initiative, aimed at improving residency training.
Angiotensin-Converting Enzyme Inhibitors May Up Lung CA Risk
TUESDAY, Oct. 30, 2018 (HealthDay News) — The use of angiotensin-converting enzyme inhibitors (ACEIs) is associated with an increased risk for lung cancer compared with angiotensin receptor blockers, according to a study published online Oct. 24 in the BMJ.
Community Health Worker Intervention Beneficial
TUESDAY, Oct. 30, 2018 (HealthDay News) — A standardized community health worker (CHW)-delivered intervention, Individual Management for Patient-Centered Targets, improves patient-perceived quality of care and reduces hospitalizations for low-income patients with chronic diseases, according to a study published online Oct. 22 in JAMA Internal Medicine.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Many Hospitals Noncompliant With Record Request Regulations
MONDAY, Oct. 29, 2018 (HealthDay News) — Among top-ranked U.S. hospitals, data reveal discrepancies in information provided to patients regarding medical records release processes as well as noncompliance with state and federal regulations, according to a study published online Oct. 5 in JAMA Network Open.
Durvalumab Extends Survival in Stage III Non-Small Cell Lung CA
MONDAY, Oct. 29, 2018 (HealthDay News) — Durvalumab results in significantly longer overall survival than placebo among patients with stage III, unresectable non-small cell lung cancer who did not have disease progression after concurrent chemoradiotherapy, according to a study published Sept. 25 in the New England Journal of Medicine.
Trump Administration Announces Plan to Cut Drug Prices
FRIDAY, Oct. 26, 2018 (HealthDay News) — In an effort to cut high drug costs, the prices paid by Medicare for certain prescription drugs would be based on those in other advanced industrial nations, according to a proposal announced Oct. 25 by the Trump administration.
Adenotonsillectomy Tied to Increase in Respiratory Tract Infections in Children 
Fractional Exhaled Nitric Oxide Elevated in Pediatric Chest Tightness Variant Asthma 
Lung Disease More Common With Ulcerative Colitis Than Crohn Disease 
Study Reveals Silicosis Rates Among Workers Fabricating Stone Countertops 
Higher Short-Term Exposure to Pollen Linked to Lower FEV1 in COPD 
Cognitive, Manual Impairment Tied to Unacceptable Inhaler Technique 
Vitamin A, D May Aid Asthma Outcomes 
.jpg)